Pfizer’s AstraZeneca takeover would give US firm substantial tax benefits

US firm stated that buyout of UK company could lower its US tax bill due to ‘tax inversion’, to avoid bringing cash back to America

Pfizer wants AstraZeneca for its pipeline of cancer treatments, but it is also keen on the substantial tax benefits that will come alongside swallowing up Britain’s second-biggest drugs firm.

Pfizer stated in its takeover proposal that buying AstraZeneca would help it avoid paying hundreds of millions of dollars in tax in the US.

Continue reading…
Pharmaceuticals industry | The Guardian

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us